351 related articles for article (PubMed ID: 21623439)
1. One-pot synthesis of sustained-released doxorubicin silica nanoparticles for aptamer targeted delivery to tumor cells.
He X; Hai L; Su J; Wang K; Wu X
Nanoscale; 2011 Jul; 3(7):2936-42. PubMed ID: 21623439
[TBL] [Abstract][Full Text] [Related]
2. In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles.
He X; Nie H; Wang K; Tan W; Wu X; Zhang P
Anal Chem; 2008 Dec; 80(24):9597-603. PubMed ID: 19007246
[TBL] [Abstract][Full Text] [Related]
3. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
Luo YL; Shiao YS; Huang YF
ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects.
Gao F; Li L; Liu T; Hao N; Liu H; Tan L; Li H; Huang X; Peng B; Yan C; Yang L; Wu X; Chen D; Tang F
Nanoscale; 2012 Jun; 4(11):3365-72. PubMed ID: 22538830
[TBL] [Abstract][Full Text] [Related]
5. One-pot green synthesis of doxorubicin loaded-silica nanoparticles for in vivo cancer therapy.
Jiang S; Hua L; Guo Z; Sun L
Mater Sci Eng C Mater Biol Appl; 2018 Sep; 90():257-263. PubMed ID: 29853089
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-responsive multifunctional magnetic nanoparticles for tumor intracellular drug delivery and imaging.
Yang Y; Aw J; Chen K; Liu F; Padmanabhan P; Hou Y; Cheng Z; Xing B
Chem Asian J; 2011 Jun; 6(6):1381-9. PubMed ID: 21548100
[TBL] [Abstract][Full Text] [Related]
7. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
8. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
10. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
11. YVO4:Eu3+ functionalized porous silica submicrospheres as delivery carriers of doxorubicin.
Cheng Z; Ma P; Hou Z; Wang W; Dai Y; Zhai X; Lin J
Dalton Trans; 2012 Feb; 41(5):1481-9. PubMed ID: 22124278
[TBL] [Abstract][Full Text] [Related]
12. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
13. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy.
Li L; Guan Y; Liu H; Hao N; Liu T; Meng X; Fu C; Li Y; Qu Q; Zhang Y; Ji S; Chen L; Chen D; Tang F
ACS Nano; 2011 Sep; 5(9):7462-70. PubMed ID: 21854047
[TBL] [Abstract][Full Text] [Related]
14. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
15.
Rainone P; De Palma A; Sudati F; Roffia V; Rigamonti V; Salvioni L; Colombo M; Ripamonti M; Spinelli AE; Mazza D; Mauri P; Moresco RM; Prosperi D; Belloli S
Int J Nanomedicine; 2021; 16():1943-1960. PubMed ID: 33727808
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
18. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
[TBL] [Abstract][Full Text] [Related]
19. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
Cho HJ; Yoon IS; Yoon HY; Koo H; Jin YJ; Ko SH; Shim JS; Kim K; Kwon IC; Kim DD
Biomaterials; 2012 Feb; 33(4):1190-200. PubMed ID: 22074664
[TBL] [Abstract][Full Text] [Related]
20. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
